Trial Profile
Safety and Efficacy of Oral Cannabidiol for GVHD Prophylaxis in Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2017 Results published in a Kalytera Therapeutics media release.
- 13 Jan 2017 Results published in a Kalytera Therapeutics media release.
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.